相关实验视频

Updated: May 10, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

使用结构导向虚拟查来识别强大的Janus激酶3抑制剂,用于炎症和瘤疾病治疗

Mohammad Y Alshahrani¹, Ali G Alkhathami¹, Mohammad Asiri¹

¹Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.

Journal of receptor and signal transduction research

|April 28, 2025

概括

研究人员通过虚拟查确定了两个潜在的Janus激酶3 (JAK3) 抑制剂,CID:68715657和CID:68585456. 这些化合物显示出开发选择性JAK3抑制剂治疗炎症和癌症疾病的前景.

科学领域:

药用化学医学化学
药理学药理学是指药理学的学科.
计算生物学计算生物学

背景情况:

简氏激酶 (JAKs) 在细胞因子信号传递和细胞增殖中至关重要,使它们成为抗炎和抗癌药物的治疗点.
开发选择性JAK抑制剂是具有挑战性的,因为高同位素同质性,但向JAK3,主要在免疫细胞,提供了一个有前途的战略.

研究的目的:

通过基于结构的虚拟查来识别对Janus激酶3 (JAK3) 有选择性的新型高亲和度抑制剂.
评估已识别的化合物作为治疗JAK3相关疾病的治疗剂的潜力.

主要方法:

使用已知的JAK3抑制剂复合结构对PubChem数据库进行基于结构的虚拟选.
应用严格的过标准,包括结构相似性,物理化学性质和分子相互作用.
使用分子动力学 (MD) 模拟和MM-PBSA计算验证化合物稳定性和结合亲和力.

主要成果:

两种化合物CID:68715657和CID:68585456被确定为潜在的高亲和力JAK3抑制剂.
这些化合物与母分子相比,与JAK3的结合亲和力和相互作用得到了改善,这表明它们的效能和选择性得到了提高.
MD模拟和MM-PBSA证实了JAK3复合物的稳定性与已识别的化合物.

结论:

CID:68715657和CID:68585456代表了开发高效和选择性的JAK3抑制剂的有希望的化合物.
需要进一步优化和实验验证,才能充分发挥它们在治疗JAK3相关炎症和癌症的治疗潜力.

关键词:

亚努斯酶 3 亚努斯酶 3 亚努斯酶通过 PASS 分析.炎症性疾病是一种炎症性疾病.分子动力学模拟,分子动力学模拟虚拟选虚拟选虚拟选

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...